Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 15/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CCR7 | P32248 | 2/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853163 | 0.93 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2CXCR2KDM4E | |
| SCHEMBL490008 | 0.84 | NPC1 (0.48) | RAB9ANPC1SMN1; SMN2CXCR2CCR7 | |
| SCHEMBL2899683 | 0.84 | NPC1 (0.48) | RAB9ANPC1SMN1; SMN2CXCR2CCR7 | |
| SCHEMBL3754582 | 0.81 | CXCR2 (0.45) | RAB9ANPC1SMN1; SMN2CXCR2KDM4E | |
| SCHEMBL3852995 | 0.79 | CXCR2 (0.49) | CXCR2CCR7CXCR1 | |
| Dimethylamine SCHEMBL3755681 | 0.78 | CXCR2 (0.46) | RAB9ANPC1CXCR2CCR7CXCR1 | |
| SCHEMBL490245 | 0.76 | CXCR2 (0.50) | CXCR2CCR7 | |
| SCHEMBL490032 | 0.76 | CXCR2 (0.47) | CXCR2CCR7 | |
| SCHEMBL490193 | 0.75 | CXCR2 (0.73) | CXCR2CCR7 | |
| SCHEMBL28010834 | 0.75 | KMT2A (0.54) | CXCR2CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111569-A1 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | BONNERT ROGER | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111569-A1 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | CXCR2, CCR5, CXCR1 | RAB9A 2346/4885NPC1 1514/4885SMN1; SMN2 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.